Experience with pegylated interferon -2a in advanced myeloproliferative neoplasms in an international cohort of 118 patientsKrisstina Gowin, Ruben A. Mesa, Prakash Thapaliya et al.|Haematologica|2012Cited by 85
Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI‐110) in Hepatocellular CarcinomaMinmin Liu, Gangning Liang, Lian Zhang et al.|Hepatology|2018Cited by 66
Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)John Mascarenhas, Robert S. Hoffman, Heidi Kosiorek et al.|Blood|2018Cited by 45
Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential ThrombocythemiaJohn Mascarenhas, Robert S. Hoffman, Josef T. Prchal et al.|Blood|2016Cited by 28
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with GuadecitabineCasey L. O’Connell, Kirsten Grønbæk, Maria R. Baer et al.|Clinical Cancer Research|2022Cited by 27